期刊文献+

30例卵巢癌患者化疗前后T淋巴细胞亚群的变化 被引量:2

The Changes of T lymphocyte subsets before and after Chemotherapy on 30 Ovarian Cancer Patients
下载PDF
导出
摘要 目的:探讨卵巢癌术后患者化疗前后T淋巴细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)的变化。方法:运用流式细胞仪检测卵巢癌术后患者化疗前及化疗后2-3周外周血T淋巴细胞亚群的数量及比例变化。结果:与化疗前比较,化疗后2-3周外周血CD3+,CD4+细胞增高,CD4+/CD8+比值增高,CD8+变化不明显。结论:化疗有助于卵巢癌患者细胞免疫功能的恢复。 Objective:To explore the changes of T lymphocyte subsets(CD3+、CD4+、CD8+、CD4+/CD8+)before and after chemotherapy on malignant Ovarian Cancer patients after their operations.Methods :After their operations, by flow cytometry, to detect the changes of quantities and ratios of T lymphocyte subsets in Ovarian Cancer patients before and during two- three weeks after the chemotherapy. Results :Compared the level before the chemotherapy, during two- three weeks after the chemotherapy, the levels of CD3+ and CD4+ cells were significantly higher,the ratio of CD4+/CD8+ increased, CD8+ cells had no obvious changes in different stage. Conclusion:The chemotherapy on malignant Ovarian Cancer patients is helpful in the recovery of the patients' immune functions of the cells.
作者 杜鸿昱 周敏
出处 《内蒙古中医药》 2014年第12期48-49,共2页 Inner Mongolia Journal of Traditional Chinese Medicine
关键词 卵巢癌术后患者 化疗 T淋巴细胞亚群 T lymphocyte subsets Chemotherapy FCM
  • 相关文献

参考文献5

二级参考文献50

  • 1赵晓东,张毅,张巧.Ⅲ期卵巢上皮癌维持化疗的初步探讨[J].中国肿瘤临床,2006,33(1):32-34. 被引量:3
  • 2陈鲁,朱笕青.卵巢癌的巩固治疗[J].国外医学(妇产科学分册),2006,33(2):135-138. 被引量:5
  • 3黄华健,朱建军.恶性肿瘤T细胞亚群检测的临床意义探讨[J].医学临床研究,2006,23(7):1043-1044. 被引量:13
  • 4Wang LX, Li R, Yang G, et al. Interleukin-7--dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing [J]. Cancer Res, 2005, 65(22): 10569-10577. 被引量:1
  • 5Shvets A, Chaka'abarti R, Gonzalez-Quintial R, et al. Impaired negative regulation of homeostatically proliferating T cells [J ]. Blood, 2009, 113(3): 622-625. 被引量:1
  • 6Brown IE, Blank C, Kline J, et al. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection [J]. J Immunol, 2006, 177(7): 4521-4529. 被引量:1
  • 7Negroni L, Samson M, Guigonis JM, et al. Treatment of colon cancer cells using the cytosine deaminase/5-fluorocytosine suicide system induces apoptosis, modulation of the proteome, and Hsp90beta phosphorylation [ J ]. Mol Cancer Ther, 2007, 6 (10): 2747-2756. 被引量:1
  • 8Stravopodis DJ, Margaritis LH, Voutainas GE. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex [J]. Curr Med Chem, 2007, 14(29): 3122-3138. 被引量:1
  • 9Storkus WJ, Herrem C, Kawabe M, et al. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen- derived Pepfide epitopes[J]. Crit Rev Immunol, 2007, 27(5): 485-93. 被引量:1
  • 10Grauer OM, Sutmuller RP, van Maren W, et al. Elimination of regulatory cells is essential for an effective vaccination with tumor lysatepulsed dendritic cells in a murine glioma model [J]. Int J Cancer, 2008, 122(8): 1794-1802. 被引量:1

共引文献59

同被引文献27

  • 1Jemal A, Bray F, Center M M, et al.Global cancer statistics [J].CA CancerJClin, 2011, 61 (2): 69-90. 被引量:1
  • 2Daudi S, Eng K H, Mhawech-Fauceglia P, et al.Expression and immune responses to MAGE antigens predict survival in epithelial ovarian Cancer[J].PLoS One, 2014, 9 ( 8 ) : el04 099. 被引量:1
  • 3Lavoue V, Thedrez A, Leveque J, et al.Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer[J].J TranslMed, 2013, 11 (1) : 147. 被引量:1
  • 4Therasse P, Arbuck S G, Eisenhauer E A, et al. New guidelines to evaluate the response to treatment in solid tumors[J].J Natl Cancer Inst, 2000, 92 ( 3 ) : 205-216. 被引量:1
  • 5Latha T S, Panati K, Gowd D S, et al.Ovarian cancer biology and immunotherapy [J].Int Rev Immunol, 2014, 33 ( 5 ) : 428-440. 被引量:1
  • 6Yigit R, Massuger L F, Figdor C G, et al.Ovarian cancer creates a suppressive microenvironment to escape immune elimination[J]. Gynecol Oncol, 2010, 117 ( 2 ) : 366-372. 被引量:1
  • 7Lesterhuis W J, De Vries I, Aarntzen E A, et al.A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatirdcapecitabine chemotherapy in colon cancer patients[J].Br J Cancer, 2010, 103 (9) : 1415-1421. 被引量:1
  • 8Cao X.Immunology in China: the past, present and future[J].Nat Immunol, 2008, 9 (4) : 339-3342. 被引量:1
  • 9Ghansah T, Vohra N, Kinney K, et al.Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma[J].Cancer Immunol Immunother, 2013, 62 (6) : 1083-1091. 被引量:1
  • 10Liu J, Li H, Cao S, et al.Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment[J].J Immunother, 2014, 37 (2): 115-122. 被引量:1

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部